Jimin Health Management Co., Ltd.’s evaluation report on the 2025 “Improving Quality, Efficiency, and Emphasis on Return” action plan and the 2026 “Improving Quality, Efficiency, and Emphasis on Return” action plan
Securities code: 603222 Securities abbreviation: Jimin Health Announcement number: 2026-028
Jimin Health Management Co., Ltd.
Regarding the 2025 “Improving Quality, Efficiency and Emphasis on Return” Action Plan Evaluation Report and the 2026 “Improving Quality, Efficiency and Emphasis on Return” Action Plan
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Jimin Health Management Co., Ltd. (hereinafter referred to as the "Company"), in order to thoroughly implement the requirements of the State Council's "Opinions on Further Improving the Quality of Listed Companies", practice the "investor-oriented" development philosophy, continue to improve corporate governance, operating efficiency and investment value, enhance investors' sense of gain, and actively respond to the Shanghai Stock Exchange's "Initiative on Carrying out the Special Action of "Improving Quality, Increasing Efficiency and Emphasizing Return" for Shanghai Stock Exchange Companies, the company continues to carry out the special action of "Improving Quality, Increasing Efficiency and Emphasizing Return", now in 2025 Evaluate the implementation of the annual "Improving Quality, Increasing Efficiency and Focusing on Returns" action plan and formulate an action plan for 2026. This plan has been reviewed and approved at the fourth meeting of the company’s sixth board of directors. The specific contents are as follows:
1. General Action Plan
The company will lay the foundation for compliance governance, improve quality and efficiency, and focus on returns to stabilize expectations. It will focus on business restoration, production capacity release, innovation transformation and shareholder returns, and promote the company to leap from the strategic adjustment period to the high-quality development period, and achieve both improvement in operational quality and efficiency and shareholder value.
2. Focus on the main business and improve operational efficiency and profitability
In 2025, the company achieved revenue of 685.963 million yuan, a decrease of 11.57% from the same period last year; it achieved net profit attributable to the parent company of -245.5825 million yuan, and suffered a large loss. The main influencing factors include: U.S. tariff policy, the "He Qinghong private seal incident" and the impairment of goodwill of Ezhou Second Hospital. In response to the above situation, the company has actively taken a number of response measures. On the one hand, in response to the impact of U.S. tariffs, the company and the U.S. RTI company are actively exploring safety syringe markets outside the United States, such as Brazil, Panama, Australia, Canada, etc.; on the other hand, in response to the "He Qinghong private seal incident", the company proactively contacted dealers to confirm the relevant inventory status and seek ways, including price discounts, to solve the above problems. For dealers with major differences and the two parties could not reach an agreement, the company actively responded to the lawsuit and protected the company's interests through legal means. In 2026, the company will continue to adhere closely to the main line of "improving quality and efficiency" and take multiple measures to promote high-quality development:
Strengthen talent support. Increase the introduction and training of high-end talents in the fields of medical care, R&D, marketing and management, and systematically improve the professional capabilities and management efficiency of the management team;
Deepen market layout. Strengthen strategic cooperation at home and abroad, deepen the development of core channels, accelerate the production and efficiency of key projects, and comprehensively improve equipment utilization, bed turnover rate and product market share;
Promote lean operations. Comprehensively implement lean management, strictly control costs and expenses, continue to optimize production and service processes, strive to improve the gross profit margin and overall profitability of each business segment, effectively reverse the situation of performance pressure, and lay a solid and sustainable operating foundation.
3. Cultivate new productive forces and create a second growth curve
(1) Continue to increase investment in innovative drug research and development
In 2025, the company continued to increase investment in the research and development of innovative drugs, incurring research and development expenses of 47.9213 million yuan, an increase of 15.18% over the same period last year. The main research and development projects promoted by the company are as follows:
Project name Registration classification Indications or functional indications R&D (registration) stage DB006 Oncolytic Disease
Class I innovative drugs, solid tumors, clinical phase I
Poison injection
ADSC-101 Category I innovative drug Retinitis pigmentosa (RP) In preclinical research stage ADSC-102 Category I innovative drug Type II diabetes (T2DM) iiT in development ADSC-103 Category I innovative drug Chronic obstructive pulmonary disease (COPD) In preclinical research phase JCDC-101 Category I innovative drug Prostate cancer iiT in development JCDC-102 Category I innovative drug Liver cancer iiT clinical study is ongoing JCDC-103 Category I innovative drug Lung cancer In preclinical research stage JICt-8801 Exploratory iiT clinical research Category I innovative drug has been completed Pan-cancer postoperative adjuvant therapy
plus study
supraventricular tachycardia or uncompensated
Esmolol hydrochloride
Chemical drug category 4, sinus tachycardia; intraoperative and postoperative pilot stage
sodium chloride injection
Tachycardia and/or hypertension
Imesil fumarate
Chemical Drug Category 4 Seasonal Allergic Conjunctivitis Validation Phase
Ting eye drops
Brimonid tartrate is suitable for reducing open-angle glaucoma and
Category 4 chemical drugs pilot stage
Fixed eye drops Intraocular pressure in patients with ocular hypertension
Oxybucaine hydrochloride
Chemical drug category 4, topical anesthesia in the field of ophthalmology, verification stage
eye drops
In 2026, the company will continue to promote the research and development of the above projects and cultivate new growth points for the company.
(2) Increase foreign investment and create a second growth curve
In 2025, the company will actively promote its foreign investment layout around the strategy of technological innovation and industrial upgrading:
In June 2025, the company subscribed RMB 150 million as a limited partner to participate in the capital increase of Hubei Changhe Intelligent Technology Entrepreneurship Development Partnership (Limited Partnership), and holds 46.88% of its equity after the investment is completed;
In September 2025, the company transferred 1.1141% of the equity of Guangzhou Dabo Biological Products Co., Ltd. held by Guangzhou Guoju Venture Capital Co., Ltd. with its own capital of 12.657 million yuan (corresponding to a capital contribution of 797,470 yuan);
In December 2025, the company and Hubei Military and Civilian Science and Technology Innovation Co., Ltd. jointly invested in the establishment of Hubei Jimin Military and Civilian Science and Technology Innovation Co., Ltd. with a registered capital of 600 million yuan. Among them, the company subscribed 294 million yuan and held 49% of the shares; the partner subscribed 306 million yuan and held 51% of the shares.
In 2026, the company will focus on growth-stage technological innovation enterprises, systematically integrate internal and external resources, accelerate industrial transformation and upgrading, focus on cultivating new performance growth points, accelerate the construction of a sustainable "second growth curve", and continue to enhance the company's long-term investment value and core competitiveness.
4. Strengthen shareholder returns and enhance investors’ sense of gain
On March 28, 2025, the company held the 17th meeting of the fifth board of directors and reviewed and approved the "Proposal on the Plan to Repurchase the Company's Shares through Centralized Bidding Transactions". It plans to use its own funds to repurchase the company's shares through centralized bidding for employee stock ownership plans or equity incentives. The repurchase price shall not exceed RMB 10.00 per share (inclusive), the total repurchase funds shall not be less than 100 million yuan (inclusive) and shall not exceed 200 million yuan (inclusive), and the repurchase period shall not exceed 12 months from the date of review and approval by the board of directors.
As of March 19, 2026, the company had repurchased a total of 11,645,140 shares through centralized bidding transactions, accounting for 2.22% of the company's total share capital. The total amount paid was 100,079,055 yuan (excluding transaction costs). It has completed the second phase of the share repurchase plan according to the established plan, and has effectively fulfilled its commitment to safeguarding the company's value and shareholders' rights.
In 2026, the company will continue to flexibly use market value management tools such as share repurchases, shareholding increases, and cancellations within the scope permitted by laws and regulations to actively maintain the stability of the company's stock price and promote the company's intrinsic value to be reasonably reflected in the capital market. At the same time, the company will continue to strengthen investor relations management, and actively communicate business progress and strategic results through regular online and offline performance briefings, institutional surveys, investor exchanges and other activities, enhance market understanding and recognition, and further enhance investors' sense of participation, recognition and gain.
5. Adhere to standardized operations and improve the corporate governance system
In 2025, the company closely followed the latest laws, regulations and regulatory requirements such as the Company Law and the Code of Governance for Listed Companies, and systematically revised core governance systems such as the Articles of Association, the Internal Audit System, and the Implementation Rules of the Special Committee of the Board of Directors to further consolidate the system foundation, ensure that the corporate governance mechanism and regulatory guidance resonate at the same frequency, and effectively improve the level of standardized operations.
In 2026, the company will continue to promote corporate governance with high standards:
Continue to improve various internal rules and regulations, optimize the governance structure, and strengthen the decision-making and execution mechanism with clear rights and responsibilities and efficient operation;
Give full play to the independence and professional role of independent directors and special committees such as the audit committee and nomination committee in major decision-making, financial supervision, and senior management selection, and improve the scientific nature and transparency of decision-making;
Adhere to the principles of true, accurate, complete, timely and fair information disclosure and build a solid compliance defense line;
Strengthen the performance management and responsibility constraints of the "key minority" such as controlling shareholders, actual controllers, directors, supervisors and senior managers, promote diligence and responsibility, and comprehensively improve corporate governance efficiency and sustainable development capabilities;
Effectively safeguard the legitimate rights and interests of all shareholders, especially small and medium-sized investors, and ensure that they enjoy fair participation and fully informed rights in corporate governance.
6. Risk warning
This plan is the company's 2026 business management and development plan and does not constitute a performance commitment. The implementation of the plan is affected by multiple factors such as macroeconomics, industry policies, market competition, project progress, etc., and there are certain uncertainties. The company will closely track changes in the internal and external environment, dynamically optimize plans and initiatives, and make every effort to promote the implementation of various goals.
Announcement is hereby made.
Jimin Health Management Co., Ltd. Board of Directors
April 30, 2026